NCT04211714View on ClinicalTrials.gov

Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

October 8, 2026

Study Completion Date

October 8, 2027

Conditions
Telomere ShorteningBone Marrow Failure
Interventions
BIOLOGICAL

EXG34217

Single infusion

Trial Locations (1)

45229

RECRUITING

Cincinnati Children's Hospital, Cincinnati

Sponsors
All Listed Sponsors
lead

Elixirgen Therapeutics, Inc.

INDUSTRY

NCT04211714 - Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure | Biotech Hunter | Biotech Hunter